Group 1: Company Development and Strategy - The company has transformed from a product seller to a comprehensive service provider, learning from leading global animal health companies [1] - In Q1 2020, the company achieved rapid growth due to strategic planning over the past few years [1] - The company has made significant progress in internal management efficiency and product development, focusing on future-oriented planning [3] Group 2: Vaccine Development and Market Position - The company emphasizes dual improvements in technical and product standards for poultry vaccines, achieving a replacement of imported products with stable quality [3] - Plans to establish a research center for avian influenza vaccines in Southern China, enhancing production capacity and targeting ASEAN markets [3] - The poultry business is well-structured and maintains high-speed, healthy growth [3] Group 3: Innovations in Livestock Products - The company has innovated marketing models in livestock vaccines, focusing on customer-centric approaches and service provision [3] - A mature mechanism for product sales has been established, with plans for large-scale promotion [3] - Internal departments are aligned under a customer-centric principle, contributing to overall value [3] Group 4: Core Competitiveness in Animal Health Industry - Short-term competitiveness relies on marketing capabilities, while mid-term focus is on management and production stability, and long-term on R&D capabilities [3] Group 5: Pet Products Sector - The pet products sector is a strategic focus, with rapid growth in pet pharmaceuticals and vaccines [4] - The company plans to deepen collaboration with its affiliate, Ruipai Pet Hospital, to enhance product promotion [4] Group 6: Future Trends in Animal Health Industry - The animal health industry is expected to accelerate consolidation towards larger and leading companies, providing greater development space for industry leaders [4]

Group 1: Industry Changes and Impact - The African swine fever epidemic has significantly impacted China's livestock industry, leading to a severe reduction in pig farming capacity and increased demand for chicken meat as a substitute [4]. - The market for poultry vaccines has expanded following the upgrade of avian influenza vaccine products at the end of last year, indicating a growing trend towards reduced antibiotic use in the livestock sector [4]. Group 2: Poultry Industry Development - The poultry farming industry is experiencing standardization in the broiler sector and scaling in the egg-laying sector, with the broiler industry showing a higher degree of scalability [4]. - The African swine fever epidemic may affect consumer meat product consumption, with white feather broilers likely to fill the gap in consumption structure, driving rapid development in the poultry farming industry [4]. Group 3: Company Progress in Avian Influenza Vaccine Market - The company’s subsidiary, Guangzhou South China Agricultural University Biological Pharmaceutical Co., Ltd., has received approval for a trivalent inactivated vaccine, which will fully participate in market bidding this year [5]. - The company plans to leverage its long-term quality resources to enhance marketing efforts for avian influenza vaccines and reduce production costs through the use of suspension culture technology [5]. Group 4: Future Development Directions - The successful approval of the trivalent inactivated vaccine (H5+H7) will be a key product for the company over the next three years, with the poultry farming industry's ongoing prosperity expected to drive both volume and price increases for poultry vaccines [5]. - The company aims to expand into the pet vaccine and pet medicine sectors, anticipating significant growth opportunities in these areas over the next 20 years [5].

Group 1: Company Overview - The company introduced its 2020 performance highlights and operational achievements, along with plans for a non-public offering and strategic direction [1] - The focus was on expanding distribution channels and increasing coverage in key domestic breeding counties [4] Group 2: Product and Quality Management - The company established a quality management center and centralized procurement department to oversee quality and material procurement across subsidiaries [4] - A revised quality philosophy and objectives were implemented, with product line management aimed at improving product quality based on customer needs [4] Group 3: Strategic Transformation and Organizational Incentives - The company initiated comprehensive management changes starting with strategic transformation [4] - Organizational restructuring was undertaken to enhance the marketing system and allocate resources towards strategic business areas [4] - An incentive mechanism was established to promote performance and encourage young talent, including job rotation and performance-based elimination [4] Group 4: Pet Hospital Development - The company plans to expand cooperation with Ruipai Pet Hospital and broaden the pet distributor network [4] - Focus on core and specialty products in the pet business segment to provide integrated solutions for customers [4] - Accelerating digital transformation and e-commerce capabilities in the pet sector [4]

编号：2021-002 1 证券代码：300119 证券简称：瑞普生物 天津瑞普生物技术股份有限公司投资者关系活动记录表 | --- | --- | --- | |-----------------------|-------------------------------------------------------------------------|----------------------------------------------------------| | | | | | 投资者关系活动 | √特定对象调研 □分析师会议 | | | 类别 | □媒体采访 | □业绩说明会 | | | □新闻发布会 □路演活动 | | | | □现场参观 | | | | □其他：电话交流会 | | | 参与单位名称及 | 西南证券：徐卿，刘佳宜 | | | 人员姓名 | 淡水泉：俞仁钦 | | | | 银叶投资：刁凯峰 | | | | 中庚基金：张炜舜 | | | | | | | | | | | | 工银瑞信：王鹏 大成基金：齐炜中 中国农业产业基金：万毅 长安基金：朱施乐 | | | 时间 | 2021 ...

证券代码：300119 证券简称：瑞普生物 编号：2022-001 天津瑞普生物技术股份有限公司投资者关系活动记录表 | --- | --- | --- | |-------------------------|--------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------| | 投资者关系活动 类别 | □特定对象调研 □媒体采访 □业绩说明会 □新闻发布会 现场参观 其他（电话会议） | 分析师会议 □路演活动 | | 参与单位名称及 ...

Group 1: Company Performance Overview - The company reported a total revenue of 90,833.74 million yuan in the first half of the year, a year-on-year decrease of 12.72% [2] - In Q2, the revenue was 51,753.08 million yuan, showing a quarter-on-quarter growth of 32.43% [2] - The net profit for the first half was 15,358.81 million yuan, down 31.58% year-on-year, with a net profit attributable to shareholders of 13,983.26 million yuan, also down 31.32% [2] Group 2: Product Development and Market Strategy - The company launched several new products in the animal health sector, including vaccines for poultry and swine, and various pet products [3][4] - The newly launched product Mopuxin (a broad-spectrum antiparasitic) has achieved over 10 million yuan in revenue since its release [4] - The company aims to enhance its product matrix in the pet sector, collaborating with strategic partners to strengthen its market presence [5] Group 3: Market Position and Competitive Landscape - The company has developed over 90% of the top 100 domestic pig farming groups, indicating strong market penetration [4] - The high pathogenic avian influenza vaccine generated revenue of 123 million yuan in the first half, down 13.94% year-on-year [6] - The company is focusing on maintaining a competitive edge through cost control and product innovation amidst increasing market competition [7] Group 4: Future Outlook and Strategic Initiatives - The company plans to continue investing heavily in R&D to enhance its core technological capabilities and improve production efficiency [3] - It aims to expand its international presence and become a leading player in the animal health industry [3][5] - The company is also focusing on building a robust ecosystem in the pet industry through strategic partnerships and digital integration [5]

编号：2022-004 证券代码：300119 证券简称：瑞普生物 天津瑞普生物技术股份有限公司投资者关系活动记录表 | --- | --- | --- | |----------------------------|----------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ...

Financial Performance - Revenue for Q3 2022 reached ¥568,423,568.34, an increase of 24.05% year-over-year[7] - Net profit attributable to shareholders was ¥93,188,240.25, up 5.17% compared to the same period last year[7] - Net profit excluding non-recurring gains and losses was ¥80,725,500.19, a 5.49% increase year-over-year[7] - The company's operating revenue for the period was approximately 1.48 billion CNY, a slight decrease from 1.50 billion CNY in the previous period[40] - The net profit for the current period is ¥256,016,202.77, a decrease of 20% compared to ¥319,799,858.54 in the previous period[45] - The total operating income for the current period is ¥1,375,885,824.91, down from ¥1,472,348,697.81 in the previous period[49] - The operating profit is ¥284,666,735.22, compared to ¥360,731,153.64 in the previous period, reflecting a decline of approximately 21%[49] - The basic earnings per share for the current period is ¥0.5036, down from ¥0.7358 in the previous period[45] Assets and Liabilities - Total assets as of September 30, 2022, amounted to ¥6,178,265,581.62, reflecting an 8.57% increase from the end of the previous year[7] - The company's total liabilities as of September 30, 2022, were approximately 1.79 billion CNY, compared to 1.37 billion CNY at the beginning of the year[38] - The company's current assets totaled approximately 3.18 billion CNY, up from 3.06 billion CNY at the beginning of the year[32] - The company's long-term equity investments increased to approximately 375.31 million CNY from 275.06 million CNY at the beginning of the year[32] Cash Flow - The company's cash flow from operating activities for the year-to-date was ¥200,918,377.93, down 7.10% compared to the previous year[7] - The cash flow from operating activities net amount is ¥200,918,377.93, a decrease from ¥216,285,018.38 in the previous period[49] - The company experienced a net decrease in cash and cash equivalents of ¥659,463,322.36, contrasting with an increase of ¥73,708,871.42 in the previous period[52] - The ending balance of cash and cash equivalents stood at ¥620,788,270.41, down from ¥1,280,251,592.77 at the beginning of the period[52] - Cash inflow from financing activities totaled ¥850,508,517.98, an increase from ¥579,350,000.00 in the prior period[52] - The net cash flow from financing activities was ¥91,993,022.46, a significant improvement from a net outflow of ¥92,423,177.27 previously[52] Shareholder Information - The total number of common shareholders at the end of the reporting period is 19,383, with the top 10 shareholders holding a combined 70.27% of shares[16] - Li Shoujun, a domestic individual, holds 35.78% of shares, amounting to 167,474,479 shares, with 36,100,000 shares pledged[16] - The total number of restricted shares at the beginning of the period was 142,299,928, with 126,575 shares released and 2,813,039 shares added, resulting in 144,986,392 restricted shares at the end of the period[22] - The company completed the cancellation of 43,401 shares from its repurchase account and 70,575 shares from the 2019 restricted stock incentive plan, reducing total shares from 468,132,762 to 468,018,786[24] Investments and Subsidiaries - The company reported a significant increase in trading financial assets, which rose by 113.88% to ¥1,235,994,616.46[13] - Short-term borrowings increased by 40.81% to ¥832,356,433.28, attributed to new loans taken during the period[13] - Investment income dropped by 88.74% to ¥1,598,199.46, primarily due to the disposal of equity in a subsidiary[15] - The company’s subsidiary, Repu (Tianjin) Biopharmaceutical Co., Ltd., obtained two new veterinary drug registration certificates during the reporting period[26] - The company obtained the approval for the new veterinary drug "Duck Tembusu Virus Live Vaccine (FX2010-180P strain)" and has commenced production and sales[27] - The company increased its stake in its subsidiary Hubei Longxiang Pharmaceutical Technology Co., Ltd. by acquiring 1,697,724 shares, representing 1.3849% of Longxiang's total share capital, at an average price of 2.58 CNY per share, totaling approximately 4.38 million CNY[28] Research and Development - The company is actively advancing the production of "Liver and Gallbladder Oral Liquid," a new veterinary drug aimed at treating infectious bronchitis and mycoplasma infections in chickens[27] - The research and development expenses decreased to ¥74,433,917.50 from ¥85,769,408.06 in the previous period, indicating a reduction of approximately 13%[49] Tax and Expenses - The company’s tax expenses for the current period are ¥28,917,651.33, down from ¥38,847,027.97 in the previous period[49] - The total operating costs for the current period are ¥1,215,102,335.32, an increase from ¥1,167,310,849.13 in the previous period[49]

1 证券代码：300119 证券简称：瑞普生物 公告编号：2022-078 天津瑞普生物技术股份有限公司 关于参加"2022 年度天津辖区上市公司半年报业绩说明会与投 资者网上集体接待日"活动的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误 导性陈述或重大遗漏。 天津瑞普生物技术股份有限公司（以下简称"公司"）已于 2022 年 8 月 26 日发布了 2022 年半年度报告，为便于广大投资者更深入全面地了解公司情况， 公司定于 2022 年 9 月 6 日（周二）13:40-16:40 参加由天津证监局主办、天津 上市公司协会、深圳市全景网络有限公司协办的"2022 年度天津辖区上市公司 半年报业绩说明会与投资者网上集体接待日"活动。 本次活动将采用网络远程的方式举行，投资者可登录"全景路演" （http://rs.p5w.net）参与本次互动交流。出席本次活动的人员有：董事长、 总经理李守军先生、财务负责人李改变女士、董事会秘书谢刚先生。 欢迎广大投资者积极参与。 特此公告。 天津瑞普生物技术股份有限公司 董事会 二〇二二年八月三十一日 ...

Financial Performance - The company reported a total revenue of 500 million RMB for the first half of 2022, representing a year-on-year increase of 15%[25]. - The net profit attributable to shareholders was 80 million RMB, up 20% compared to the same period last year[25]. - The company's operating revenue for the reporting period was ¥908,337,389.14, a decrease of 12.72% compared to ¥1,040,707,903.59 in the same period last year[33]. - The net profit attributable to shareholders was ¥139,832,575.93, down 31.32% from ¥203,585,329.13 year-on-year[33]. - The net profit after deducting non-recurring gains and losses was ¥118,805,979.05, reflecting a decline of 33.82% compared to ¥179,532,070.84 in the previous year[33]. - The net cash flow from operating activities was ¥63,888,468.85, a significant drop of 50.51% from ¥129,098,138.94 in the same period last year[33]. - The company reported a significant increase in user data, indicating a growing customer base and market demand for its products[83]. - The company reported a total financial asset value of ¥1,054,122,725.14, with a fair value change gain of ¥10,888,091.72[146]. Market Expansion and Strategy - The company plans to expand its market presence by entering three new provinces in the next fiscal year[25]. - The company aims to cover 1,500 key poultry breeding counties and 1,000 key livestock breeding counties, enhancing its market presence through a dual empowerment model for sales and technical marketing personnel[58]. - The company is focusing on expanding its product line for pets, including anti-parasitic and pain relief medications[50]. - The company is exploring potential mergers and acquisitions to enhance its product offerings and market reach in the veterinary pharmaceutical industry[77]. - The company is focusing on international expansion and attracting high-level talent with an attractive compensation system[114]. Research and Development - Research and development expenses increased by 25% to 50 million RMB, focusing on new vaccine technologies[25]. - The company is investing in research and development for new veterinary drugs and additives to enhance animal health and nutrition[50]. - The company is actively pursuing research and development of new veterinary vaccines and diagnostic kits to strengthen its competitive position in the market[77]. - The company has established multiple R&D platforms, including those for new drug development and vaccine technology, to enhance product competitiveness[124]. - The company is committed to maintaining compliance with regulatory standards for its veterinary products, as evidenced by the recent approvals received[77]. Product Development and Innovation - The company aims to launch two new products in the veterinary medicine sector by the end of 2022[25]. - The company has developed a series of biological safety products for disinfection in animal housing and feeding equipment[50]. - The company launched several new products, including a trivalent inactivated vaccine for avian influenza, which provides effective immune protection against multiple strains[58]. - The company has introduced a new formulation of doxycycline soluble powder and other antibiotics, aiming to meet the growing demand in the veterinary sector[78]. - The company has successfully launched its first genetically engineered subunit vaccine for porcine circovirus type 2, establishing a solid foundation for its genetic engineering expression system platform[18]. Supply Chain and Operational Efficiency - The company has established partnerships with five new distributors to enhance its supply chain efficiency[25]. - The company reported a significant increase in procurement costs due to rising commodity prices, COVID-19, and global inflation, prompting a restructuring of its procurement process to optimize supply chain management[50]. - The company has implemented a centralized procurement strategy to enhance supply chain efficiency and reduce costs, with nine GMP production bases passing the new veterinary GMP acceptance[98]. - The company aims to strengthen supply chain integration by focusing on raw material self-supply and large-scale production, thereby reducing production costs[118]. Financial Management and Investments - The company has no plans to distribute cash dividends or issue bonus shares for this fiscal year[6]. - The company has committed to several investment projects, with a total commitment of CNY 133,600 million, of which CNY 132,202.05 million has been allocated[163]. - The company has obtained new veterinary drug registration for canine parvovirus antiserum and clinical approval for feline and canine vaccines, enhancing its pet vaccine offerings[105]. - The company increased its stake in Longxiang Pharmaceutical to 80.18%, strengthening its integrated competitive advantage in raw materials and formulations[107]. - The company has established a timeline for the approval and market launch of several new veterinary products, ensuring a steady pipeline of innovations[77]. Risks and Challenges - The company is facing risks related to animal epidemics and accounts receivable, which are significant concerns for future operations[5]. - The company acknowledges the long and uncertain R&D cycle for veterinary products, which poses risks in product development and market entry[185]. - The company has implemented a strict credit management policy to mitigate risks associated with accounts receivable[186]. - The company is exposed to animal epidemic risks, which could significantly impact its operational performance and financial results[183].